This Week in Oncology — Jun 11, 2026

Welcome to This Week in Oncology. This week we're covering 8 notable papers spanning the rise of artificial intelligence in pathology, refinements in immunotherapy, and new insights from molecular biomarkers. Let's dive in.

We begin with a major emerging theme: the use of artificial intelligence to extract deeper meaning from routine pathology slides.
This week's papers:
• TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial. — Clinical cancer research : an official journal of the American Association for Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42268339)
• Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial. — Nature medicine 2026 (pubmed.ncbi.nlm.nih.gov/42260101)
• First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. — Nature cancer 2026 (pubmed.ncbi.nlm.nih.gov/42259988)
• GPR15-guided CD8T regulatory cells control intestinal inflammation. — Nature 2026 (pubmed.ncbi.nlm.nih.gov/42259915)
• Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling. — Cancer cell 2026 (pubmed.ncbi.nlm.nih.gov/42259249)
• Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images. — Cancer research 2026 (pubmed.ncbi.nlm.nih.gov/42258704)
• ESGO Statements on Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma. — JAMA 2026 (pubmed.ncbi.nlm.nih.gov/42258227)
• Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer. — Annals of oncology : official journal of the European Society for Medical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42250604)
• Pathogenesis of diffuse large B cell lymphoma proteogenotypes. — Cancer cell 2026 (pubmed.ncbi.nlm.nih.gov/42242231)
Listen at AudioScholar (audioscholar.cc/episode/yfceaz4v6d)